BioSpace News Archive

Annual report found market share changed as players dropped out.

Acquisition Expands Lilly Oncology Pipeline with Early-Phase Asset Being Studied in Multiple Tumor Types

First generic bioequivalent to MacroBID® on the Canadian market

BRIVIACT CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures

In a preclinical study, Toca 521 reversed PD-1/PD-L1 mediated immune suppression

Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation of a Phase 1 clinical trial of its novel oral beta-lactamase inhibitor ETX0282. ETX0282CPDP, the combination of ETX0282 with cefpodoxime, is being developed as an oral therapy for infections caused by multidrug-resistant (MDR) Gram-negative pathogens, including MDR and carbapenem-resistant Enterobacteriaceae (CRE).

Myomo is a wearable robotics company.

Immunopheresis™ therapy is a proprietary technology that selectively removes immune inhibitors from a patient’s bloodstream potentially enabling their natural immune system to more-effectively attack cancer tumors.

The Company has a strategic agreement with a leading Urology distribution partner

Zynex, Inc. (OTCQB: ZYXI), today announced a program to buy back an additional $2 million of the Company’s common stock